. Author manuscript; available in PMC: 2019 Oct 1.

Published in final edited form as: Pharmacol Res. 2018 Sep 13;136:140–150. doi: 10.1016/j.phrs.2018.09.007

Table 3:

Change in bone turnover biomarkers pre and post 14 days of vamorolone therapy. Abbreviations: CTX = C- terminal telopeptide; P1NP = procollagen type 1 pro-peptide

Vamorolone dose	Biomarker	Visit	N	Mean	SD	Paired t-test p-value
0.25 mg/kg/day	Osteocalcin (ng/mL)	Baseline	12	37.9	11.6	ns
		Week 2	12	38.5	12	ns
	CTX (pg/mL)	Baseline	11	871	161	ns
		Week 2	12	964	158	ns
	P1NP (ng/mL)	Baseline	12	556	185	0.01
		Week 2	12	444	93.9	0.01
0.75 mg/kg/day	Osteocalcin (ng/mL)	Baseline	8	34.8	7.7	ns
		Week 2	10	34.8	9.1	ns
	CTX (pg/mL)	Baseline	8	915	281	ns
		Week 2	10	913	276	ns
	P1NP (ng/mL)	Baseline	8	472	121	ns
		Week 2	10	417	98.5	ns
2.0 mg/kg/day	Osteocalcin (ng/mL)	Baseline	10	40.8	6.13	ns
		Week 2	10	36.5	9.16	ns
	CTX (pg/mL)	Baseline	10	905	265	0.006
		Week 2	10	675	172	0.006
	P1NP (ng/mL)	Baseline	10	519	96	<0.001
		Week 2	10	341	72.9	<0.001
6.0 mg/kg/day	Osteocalcin (ng/mL)	Baseline	10	44.8	6.33	<0.001
		Week 2	10	29.9	4.69	<0.001
	CTX (pg/mL)	Baseline	10	904	203	<0.001
		Week 2	10	649	205	<0.001
	P1NP (ng/mL)	Baseline	10	516	116	<0.001
		Week 2	10	310	59	<0.001